![]() |
|
|
Vol. 302, Issue 2, 490-496, August 2002
Laboratories of Biochemistry, University of Pennsylvania, School of
Veterinary Medicine, Philadelphia, Pennsylvania
Neonatal administration of monosodium glutamate (MSG) can produce
latently expressed defects in drug metabolism and growth hormone
secretion as well as stunted growth and obesity. Instead of secreting
growth hormone in the masculine episodic profile, plasma hormone
levels are generally undetectable in affected adult male rats.
Moreover, male-specific isoforms of cytochrome P450 (P450; e.g.,
CYP2C11 and CYP3A2), whose combined levels comprise the bulk of the
total hepatic P450 in adult male rats, are similarly undetectable in
these animals. Since "signaling elements" in the masculine episodic
growth hormone profile are solely responsible for the elevated
characteristic male-like expression levels of CYP2C11 and CYP3A2,
suppression of the isoforms in the MSG-treated rats appeared to be
caused by the simple absence of the hormone from the circulation.
However, the reported failures of restored physiologic masculine growth
hormone profiles to correct the P450 defects suggested the occurrence
of direct MSG-induced liver damage independent of the well known
hypothalamic lesions produced by the amino acid. Concurrent
administration of dizocilpine maleate (MK-801), a selective and highly
potent noncompetitive N-methyl-D-aspartate receptor antagonist of glutamate, completely prevented the adverse effects of neonatal MSG treatment on P450 expression, growth hormone secretion, and growth parameters, indicating that the amino
acid-induced defects are solely a result of neuronal (i.e.,
hypothalamic) damage produced at the time of MSG exposure. The
irreversibility of the P450 damage is described as resulting from
secondary defects initially induced by the neuronal lesions.